Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acasti Pharma Inc. (V:ACST)

Business Focus: Pharmaceuticals (NEC)

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 3009
Boul. De La Concorde East, Suite 102
LAVAL QC H7E 2B5
Tel: 1-617-3084306
Website: https://www.acasti.com/en
IR: See website
Key People
Roderick Noel Carter
Independent Chairman of the Board
Prashant Kohli
Chief Executive Officer
Robert J. Delaversano
Principal Financial Officer, Principal Accounting Officer
Carrie D'Andrea
Vice President - Clinical Operations
Amresh Kumar
Vice President - Program Management
R. Loch Macdonald
Chief Medical Officer
Business Overview
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company's clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
Financial Overview
For the nine months ended 31 December 2023, Acasti Pharma Inc revenues was not reported. Net loss decreased 27% to $9.7M. Lower net loss reflects Research and development expenses - Bala decrease of 82% to $1.1M (expense), Salaries and benefits decrease of 46% to $807K (expense), Interest income increase from $64K to $662K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.80 to -$1.18.
Employees: 32 as of Mar 31, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $7.08M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$12.21M as of Dec 31, 2023
Net annual income (TTM): -$38.77M as of Dec 31, 2023
Free cash flow (TTM): -$13.58M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 9,399,404 as of Dec 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization